Pfizer to end development of experimental obesity pill due to elevated liver enzymes

Indonesia Berita Berita

Pfizer to end development of experimental obesity pill due to elevated liver enzymes
Indonesia Berita Terbaru,Indonesia Berita utama
  • 📰 CNBC
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 72%

Pfizer's two pills are part of the same class of obesity drugs as Novo Nordisk's blockbuster weight loss injections Ozempic and Wegovy.

, due to elevated liver enzymes in patients who took the drug once a day in mid-stage clinical studies.often indicate damage to cells in the liver, but the pharmaceutical giant said no patients experienced liver-related symptoms or side effects., danuglipron, which is in a fully enrolled phase two clinical trial.

"We look forward to analyzing the danuglipron Phase 2 results and selecting the dose and titration schedule that will maximize the therapeutic benefit and safety and tolerability," William Sessa, Pfizer's chief scientific officer of internal medicine, said in a press release.'s blockbuster weight loss injections Ozempic and Wegovy are part of a class of drugs called glucagon-like peptide-1 agonists.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

CNBC /  🏆 12. in US

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Pfizer scraps one weight loss drug in race to develop Ozempic rivalPfizer Inc said on Monday it will drop the development of experimental obesity and diabetes drug lotiglipron and focus on another treatment, as the drugmaker races to tap the promising market for weight loss drugs.
Baca lebih lajut »

Novo Nordisk says obesity pill leads to 15% weight loss; availability 'to be determined'Novo Nordisk says obesity pill leads to 15% weight loss; availability 'to be determined'Drugmaker Novo Nordisk on Sunday said a late-stage trial found that a high-dose oral version of its drug semaglutide helped overweight or obese adults lose 15% of their body weight, which is in line with recent results for other experimental obesity pills.
Baca lebih lajut »

Tesla stock slips on downgrade, IBM shares ease on reported deal and other stocks on the moveIBM, Tesla and Novo Nordisk are some of the stocks on the move.
Baca lebih lajut »

Jackie Goldschneider: I’ll be the only ‘Housewife’ not on Ozempic at this rateJackie Goldschneider: I’ll be the only ‘Housewife’ not on Ozempic at this rateThe “RHONJ” star responded on Instagram after fans accused fellow Bravolebrity Emily Simpson of using the diabetes drug to lose weight.
Baca lebih lajut »

'You Don't Know Me': RHOC's Emily Claps Back At Accusation She Uses Ozempic'You Don't Know Me': RHOC's Emily Claps Back At Accusation She Uses Ozempic‘Real Housewives of Orange County’ star Emily Simpson has responded to claims that she is using Ozempic to lose weight — read more
Baca lebih lajut »

Can Ozempic Cure Addiction?Can Ozempic Cure Addiction?Today on What Next TBD: The FDA says to take Ozempic for diabetes. But millions use it for weight loss. And now some say - it could cure addiction.
Baca lebih lajut »



Render Time: 2025-02-27 15:11:16